{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:57:58Z","timestamp":1787025478939,"version":"build-2736575974"},"reference-count":21,"publisher":"Society of Nuclear Medicine","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2025,10,15]]},"published-print":{"date-parts":[[2026,1]]},"DOI":"10.2967\/jnumed.125.270710","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T16:00:22Z","timestamp":1764086422000},"page":"71-78","source":"Crossref","is-referenced-by-count":3,"title":["Primary Staging of Intermediate- and High-Risk Prostate Cancer Using [\n                    <sup>18<\/sup>\n                    F]PSMA-1007 PET\/CT and [\n                    <sup>18<\/sup>\n                    F]NaF PET\/CT: A Head-to-Head Comparison of Diagnostic Accuracy, Staging, and Patient Management"],"prefix":"10.2967","volume":"67","author":[{"given":"Karen M.","family":"Buch-Olsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mie H.","family":"Vilstrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steinbj\u00f8rn","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mads H.","family":"Poulsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paw C.","family":"Holdgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karsten E.A.","family":"Zieger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorun","family":"Holm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasper T.","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren","family":"Hess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Eiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oke","family":"Gerke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malene G.","family":"Hildebrandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"key":"2026010206300915000_67.1.71.1","unstructured":"Prostate cancer statistics. World Cancer Research Fund website. https:\/\/www.wcrf.org\/cancer-trends\/prostate-cancer-statistics\/. Accessed August 28, 2025."},{"key":"2026010206300915000_67.1.71.2","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer\u20142024 update. Part I: screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol."},{"key":"2026010206300915000_67.1.71.3","unstructured":"Prostate cancer guidelines. American Urological Association website. https:\/\/www.auanet.org\/guidelines-and-quality\/guidelines\/oncology-guidelines\/prostate-cancer. Accessed May 5, 2025."},{"key":"2026010206300915000_67.1.71.4","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). National Comprehensive Cancer Network website. https:\/\/www.nccn.org\/guidelines\/category_1. Accessed February 17, 2025."},{"key":"2026010206300915000_67.1.71.5","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/S1470-2045(22)00642-8","article-title":"Intra-individual comparison of 18F-sodium fluoride PET-CT and 99mTc bone scintigraphy with SPECT in patients with prostate cancer or breast cancer at high risk for skeletal metastases (MITNEC-A1): a multicentre, phase 3 trial","volume":"23","author":"B\u00e9nard","year":"2022","journal-title":"Lancet Oncol."},{"key":"2026010206300915000_67.1.71.6","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1007\/s00256-019-03230-z","article-title":"Comparison of PSMA-PET\/CT, choline-PET\/CT, NaF-PET\/CT, MRI, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a systematic review and meta-analysis","volume":"48","author":"Zhou","year":"2019","journal-title":"Skeletal Radiol."},{"key":"2026010206300915000_67.1.71.7","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.3390\/diagnostics12112594","article-title":"PSMA PET-CT in the diagnosis and staging of prostate cancer","volume":"12","author":"Combes","year":"2022","journal-title":"Diagnostics."},{"key":"2026010206300915000_67.1.71.8","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/MNM.0000000000001110","article-title":"In primary lymph nodal staging of patients with high-risk and intermediate-risk prostate cancer, how critical is the role of gallium-68 prostate-specific membrane antigen positron emission tomography-computed tomography?","volume":"41","author":"Kulkarni","year":"2020","journal-title":"Nucl Med Commun."},{"key":"2026010206300915000_67.1.71.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.03.001"},{"key":"2026010206300915000_67.1.71.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2015.12.025"},{"key":"2026010206300915000_67.1.71.11","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s00345-019-02846-z","article-title":"68Ga-PSMA PET\/CT compared with MRI\/CT and diffusion-weighted MRI for primary lymph node staging prior to definitive radiotherapy in prostate cancer: a prospective diagnostic test accuracy study","volume":"38","author":"Petersen","year":"2020","journal-title":"World J Urol."},{"key":"2026010206300915000_67.1.71.12","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13550-020-00618-0","article-title":"Added value of 68Ga-PSMA PET\/CT for the detection of bone metastases in patients with newly diagnosed prostate cancer and a previous 99mTc bone scintigraphy","volume":"10","author":"Zacho","year":"2020","journal-title":"EJNMMI Res."},{"key":"2026010206300915000_67.1.71.13","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.268275"},{"key":"2026010206300915000_67.1.71.14","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.eururo.2023.09.003","article-title":"European Association of Nuclear Medicine focus 5: consensus on molecular imaging and theranostics in prostate cancer","volume":"85","author":"Oprea-Lager","year":"2024","journal-title":"Eur Urol."},{"key":"2026010206300915000_67.1.71.15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30314-7"},{"key":"2026010206300915000_67.1.71.16","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/bco2.243","article-title":"A randomised trial of [18F]PSMA-1007-PET\/CT versus NaF-PET\/CT for staging primary prostate cancer: a trial protocol","volume":"4","author":"Buch-Olsen","year":"2023","journal-title":"BJUI Compass."},{"key":"2026010206300915000_67.1.71.17","unstructured":"Proportions and their differences. In: Altman DG , Machin D , Bryant TN , Gardner MJ , eds. Statistics with Confidence. 2nd ed. BMJ Books; 2000."},{"key":"2026010206300915000_67.1.71.18","doi-asserted-by":"crossref","first-page":"470","DOI":"10.3414\/ME0540","article-title":"PET\/CT in cancer: Methodological considerations for comparative diagnostic phase II studies with paired binary data","volume":"47","author":"Gerke","year":"2008","journal-title":"Methods Inf Med."},{"key":"2026010206300915000_67.1.71.19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d2304"},{"key":"2026010206300915000_67.1.71.20","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s00259-020-04782-2","article-title":"18F-DCFPyL PET\/CT for primary staging in 160 high-risk prostate cancer patients; metastasis detection rate, influence on clinical management and preliminary results of treatment efficacy","volume":"48","author":"Wondergem","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026010206300915000_67.1.71.21","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1053\/j.semnuclmed.2023.11.001","article-title":"A practical guide to the pearls and pitfalls of PSMA PET imaging","volume":"54","author":"Voter","year":"2024","journal-title":"Semin Nucl Med."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.125.270710","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T14:31:14Z","timestamp":1767364274000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.125.270710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,2]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.2967\/jnumed.125.270710"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.125.270710","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]}}}